Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.

(Reuters) -Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.

June 13 (Reuters) - Moderna's shares (MRNA.O), opens new tab fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory ...

Moderna Falls on Doubts Over New CDC Panel's Backing of RSV Vaccine By Mariam Sunny (Reuters) -Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back ...